Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Ruxolitinib is used to treat myelofibrosis, a rare bone marrow cancer that disrupts your body's normal blood cell production. Some people taking this drug, however, keep having symptoms. Researchers want to see if adding the drug ulixertinib to ruxolitinib treatment is safe and works better to treat myelofibrosis.
DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.
The purpose of this study is to find the highest dose of the investigational drug NVL-655 that can be given safely in people with advanced non-small cell lung cancer (NSCLC) or other solid tumors that contain a genetic change called an ALK gene fusion. NVL-655 is a type of drug called a tyrosine kinase inhibitor (TKI), which works by blocking proteins that fuel cancer growth. However, some cancer cells develop resistance to TKI treatment.
Researchers want to find the best dose of VLS-1488 to treat various types of advanced cancer. VLS-1488 blocks KIF18A, a protein that plays a role in the rapid growth of cancer cells. By blocking KIF18A, VLS-1488 may cause cancer cells to stop growing and die. VLS-1488 is taken orally (by mouth).
Researchers want to see how well ivosidenib works to treat conventional chondrosarcoma that has metastasized (spread). Chondrosarcoma is a type of bone cancer that forms in cartilage cells. The people in this study have metastatic conventional chondrosarcoma that has a mutation (change) in the IDH1 gene.
Researchers want to see if a lower dose of radiation therapy works as well as the standard dose in people with lymphoma. The people in this study have B-cell lymphoma that has not yet been treated.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Hyperthermic intraperitoneal chemotherapy (HIPEC) involves giving heated chemotherapy directly into the belly immediately after surgery to remove an abdominal cancer. Researchers are doing this study to see if HIPEC improves outcomes in people with ovarian cancer. The people in this study have newly diagnosed stage 3 or 4 ovarian cancer.
The purpose of this study is to evaluate the safety and effectiveness of cesium-131 (Cs-131) brachytherapy in patients with brain cancer that has come back after prior radiation therapy and who will be having surgery to remove it. Brachytherapy involves the placement of radioactive seeds into the brain during surgery. The seeds remain in place permanently in the area where the tumor was removed and give off cancer-killing radiation temporarily.
This purpose of this study is to assess two interventions to improve cancer care for older adults with cancer. Patients will be randomly assigned to one of the two interventions, which each consist of four surveys, five telephone sessions, and four subsequent "booster" calls with a licensed mental health counselor. The five telephone sessions each last about 45-60 minutes; the booster calls each last approximately 20-30 minutes. These surveys will include questions about each patient's illness, quality of life, depression, anxiety, and attitudes about aging and can be done via computer or over the phone. Patients will be compensated for their participation.
